跳至主要内容
临床试验/NL-OMON21690
NL-OMON21690招募中不适用

Quantitative sensory testing and intraepidermal nerve fiber density for improved diagnosis of Fabry disease.

TIpharma consortiumAcademia: Amcpharma: Genzyme, a sanofy companysubsidizing party: Shire HGT0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
25

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • Decrease in alpha-galactosidase A activity in leucocytes, plasma or fibroblasts
  • according to local laboratory criteria AND presence of a mutation in the alpha-
  • galactosidase A gene of uncertain clinical relevance.

排除标准

  • Patient is unwilling to participate.

研究者

发起方
TIpharma consortiumAcademia: Amcpharma: Genzyme, a sanofy companysubsidizing party: Shire HGT

相似试验

Assessing small fiber neuropathy for improved... | 临床试验